Drug Profile
Research programme: phosphodiesterase V inhibitors - Plexxikon
Alternative Names: Phosphodiesterase V inhibitors research programme - PlexxikonLatest Information Update: 07 Jul 2022
Price :
$50
*
At a glance
- Originator Plexxikon
- Class
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 06 Jul 2022 Discontinued - Preclinical for Erectile dysfunction in USA (unspecified route)
- 10 Mar 2008 No development reported - Preclinical for Erectile dysfunction in USA (unspecified route)
- 27 Feb 2004 Compounds from this programme are available for licensing (http://www.plexxikon.com/)